KITS AND REAGENTS
KITS AND REAGENTS
Quidel is a leading manufacturer of diagnostic healthcare solutions serving toenhance the health and well-being of people around the globe through the
development of diagnostic solutions that can lead to improved patient
outcomes and provide economic benefits to the healthcare system.
Our product base and technology platforms have continued to expand
through internal development and acquisitions of other products and
technologies allowing for a core competency that includes:
Immuno and molecular assay development
Automated manufacturing lateral flow (LF) technologies
Direct fluorescent antibodies(DFA) production
Monoclonal antibody characterization
Quidel Specialty Products is the option for all your research, biosafety, and
cytotoxicity testing needs. Quidel MicroVue products are a well-established
name in immune system monitoring, assays for the assessment of
Complement activation, as well as biochemical bone markers. Quidel offers
products to meet biosafety testing and Complement dependent cytotoxicity
testing needs, such as normal human sera, cobra venom factor and
Complement fragment assays. ELISA assays, depleted sera, proteins,
monoclonal and polyclonal antibodies, antisera, antigens, controls, and
special reagents are also available to round-out a comprehensive laboratory
portfolio.
Quidel Specialty Products is the option for all yourresearch, biosafety and cytotoxicity testing needs.
Research to RapidsThe Complement System consists of more than 30 fluid and membrane-bound proteins organized into four
primary pathways: the Classical, Alternative, Lectin and Terminal.1 By a series of specific activation steps via
either the classical, alternative, or the lectin pathway, the complement proteins mediate a set of activities
ranging from the initiation of inflammation, clearance of immune complexes, disruption of cell membranes, and
regulation of the immune response. Deficiencies in the complement cascade can predispose individuals to
infection through ineffective opsonization or defects in the ability to lyse invading pathogens. Conversely, the
inflammation promoted by activation of the complement system can lead to tissue damage, such as in ischemia
reperfusion injury, if not kept in check. Complement proteins and fragments are also believed to play a role in
several autoimmune diseases including rheumatoid arthritis, SLE and acute glomerulonephritis.2
DIAGNOSTIC EIA KITSFor In Vitro Diagnostic Use*
Diagnostic kits and controls for assessment of twotypes of circulating immune complexes (CIC),diagnosis of hereditary angioedema (HAE) andmeasurement of total classical pathway activity.
Catalog # Qty Description A001 (CE) 1 kit MicroVue CIC-C1q EIA (Detection
of C1q-binding circulating immunecomplexes)
A002 (CE) 1 kit MicroVue CIC-Raji Cell ReplacementEIA (Detection of C3d-boundcirculating immune complexes)
A013 (CE) 1 set MicroVue ClC-C1q ControlsA018 (CE) 1 kit MicroVue CH50 Eq EIA (Classical
complement pathway activity)A027 (CE) 1 kit MicroVue Bb Plus Fragment EIA A037 (CE) 1 kit MicroVue C1-lnhibitor Plus EIA
(Functional C1-lnhibitor levels)
*All MicroVue Complement IVD products are also CE marked.
EIA KITS FOR COMPLEMENTACTIVITATION ANALYSIS
These kits allow for the analysis of activation of keyproteins and specific pathways of the complementsystem in serum, plasma, and other biological fluids.
Catalog # Qty Description A006 1 kit MicroVue iC3b EIA**
(For C3 activation)A008 1 kit MicroVue C4d Fragment EIA**
(For C4 and classical pathway)A020/A029 (CE) 1 kit MicroVue SC5b-9 Plus EIA**
(For MAC assembly, TCC, C5 andterminal pathway activation)
A021/A025 (CE) 1 kit MicroVue C5a EIA***A031/A032 (CE) 1 kit MicroVue C3a Plus EIA***
(For C3 activation)A033/A034 (CE) 1 kit MicroVue Ba Fragment EIA**A035/A036 (CE) 1 kit MicroVue C4a Fragment EIA**A039/A040 (CE) 1 kit MicroVue Factor H EIA**20261 1 kit MicroVue Pan-Specific C3
Reagent Kit**BP029 1 kit MBL Oligomer EIA**TE1038 1 kit C3a Mouse**
EIA KITS FOR ASSESSMENT OFPREKALLIKREIN ACTIVATOR LEVEL
Assay kits for the determination of PrekallikreinActivator levels in biological fluids.
Catalog # Qty Description PW30100 1 kit Prekallikrein Activator (PKA)
Assay Kit**PW301EP 1 kit Prekallikrein Activator (PKA)
EP Assay Kit**PW30200 1 kit Prekallikrein Activator (PKA)
Ig Assay Kit**PW302EP 1 kit Prekallikrein Activator (PKA)
Ig EP Assay Kit**PW51005 5 x 0.5 mL Just Positive PKA ControlPW52005 5 x 0.5 mL High Positive PKA Control**For Research Use Only. Not for use in diagnostic procedures.***For Research Use Only in the United States. Not for use indiagnostic procedures. CE marked.
References 1Liszewicki, MK and Atkinson, JP. The Complement System.In: Fundamental Immunology. Paul, WE (ed.) (1993).2Botto, M et al. Complement in human diseases: Lessonsfrom complement deficiencies. Mol. Immunol. 46(4):2774-2783 (2009).
SPECIAL COMPLEMENT REAGENTSCatalog # Vol./Vial Description A100 1.0 mL Human Complement Standard††
(normal human serum)A112 2.5 mL Normal Human Serum ComplementA113 5.0 mL Normal Human Serum ComplementA114 0.2 mL Complement Activator (heat
aggregated gamma globulin)A115 1 Panel Complement Sample Panel (10
Samples x 25 µL)A119 5.0 mL Guinea Pig Serum ComplementA121 2.0 mL Guinea Pig Serum ComplementA600 1.0 mg CVF, Cobra Venom Factor (Naja naja
kaouthia)†A9576 25.0 mL Specimen Stabilizing Solution†>350 units/vial††The Human Complement Standard comes with a data sheetindicating the functional activity and antigen levels of each of themajor complement proteins.
HUMAN COMPLEMENT REAGENTS: ANTISERAFor Research Use OnlyQuidel’s complement antisera are raised in goats andare quality controlled for specificity byimmunochemical analysis. Each contains 0.02%sodium azide.
Catalog # Vol./Vial Description A300 2.0 mL Anti-human C1-lnhibitorA301 2.0 mL Anti-human C1qA302 2.0 mL Anti-human C1sA303 1.0 mL Anti-human C2 (Ig Fraction)A304 2.0 mL Anti-human C3A305 2.0 mL Anti-human C4A306 2.0 mL Anti-human C5A307 2.0 mL Anti-human C6A308 2.0 mL Anti-human C7A309 2.0 mL Anti-human C8A310 2.0 mL Anti-human C9A311 2.0 mL Anti-human Factor BA312 2.0 mL Anti-human Factor HA313 2.0 mL Anti-human Factor I
BIOTINYLATED MONOCLONAL ANTIBODIESFor Research Use OnlyEach monoclonal antibody has been purified fromascites fluid and labeled with biotin. The proteinconcentration of each is approximately 0.2 mg/mL.
Catalog # Vol./Vial Description A700 250 µL Anti-human C1qA701 250 µL Anti-human C3cA702 250 µL Anti-human C3dA703 250 µL Anti-human C4cA704 250 µL Anti-human C4dA705 250 µL Anti-human C5A706 250 µL Anti-human C6A707 250 µL Anti-human C7A708 250 µL Anti-human C8A709 250 µL Anti-human C9A710 250 µL Anti-human iC3b (neoantigen)A711 250 µL Anti-human SC5b-9 (neoantigen)A712 250 µL Anti-human Factor B (Bb)
CUSTOM PRODUCTSFor more information about customized or non-catalog product possibilities, please contact Quidel oryour local representative.
HUMAN COMPLEMENT REAGENTS: PROTEINSFor Research Use OnlyEach complement protein has been tested forfunctional purity in standard hemolytic assays and forbiochemical purity by SDS-polyacrylamide gelelectrophoresis. The concentration of eachcomplement protein, except for Factor D and C3a, isapproximately 1.0 mg/mL.
Catalog # Vol./Vial Description A400 1.0 mL C1q†A401 250 µL C3A402 250 µL C4A403 250 µL C5A404 250 µL C6A405 250 µL C7A406 250 µL C8A407 250 µL C9A408 250 µL Factor BA409 250 µL Factor D††A410 250 µL Factor HA411 250 µL Factor IA412 250 µL Factor PA413 50 µL C3bA414 100 µL C3aA415 100 µL SC5b-9 Complex
†In phosphate buffered saline containing 40% glycerol.††The protein concentration for Factor D is 0.1 mg/mL.
COMPLEMENT REAGENTS: DEPLETED OR DEFICIENT SERA
For Research Use OnlyExcept for the C3-dpl, C3/C4-dpl and the C4-deficientguinea pig sera, a specific complement protein hasbeen removed immunochemically from each depletedhuman serum reagent. Depleted sera are well suitedfor the detection and quantitation of hemolyticallyactive complement proteins. Except for the specificallydepleted component, the classical and alternativepathways are intact.
Catalog # Vol./Vial Description A500 1.0 mL C2-dplA501 1.0 mL C5-dplA502 1.0 mL C6-dplA503 1.0 mL C7-dplA504 1.0 mL C8-dplA505 1.0 mL C9-dplA506 1.0 mL Factor B-dplA507 1.0 mL C4-deficient (guinea pig)A508 1.0 mL C3-dplA509 1.0 mL C1q*-dplA512 1.0 mL Factor P-dplA521 1.0 mL C3/C4-dplA522 1.0 mL C4-dplA523 1.0 mL Factor I-dplA524 1.0 mL Factor H-dpl
HUMAN COMPLEMENT REAGENTS:MONOCLONAL ANTIBODIES
For Research Use OnlyEach monoclonal antibody has been purified frommouse ascites fluid and tested for purity by SDS-polyacrylamide gel electrophoresis. The proteinconcentration of each is approximately 1 mg/mL inborate buffered saline with 0.1% sodium azide.
Catalog # Vol./Vial Description A201 100 µL Anti-human C1qA203 100 µL Anti-human C3aA205 100 µL Anti-human C3 (C3c)A207 100 µL Anti-human C3 (C3d)A209 100 µL Anti-human iC3b (neoantigen)A211 100 µL Anti-human C4 (C4c)A213 100 µL Anti-human C4 (C4d)A215 100 µL Anti-human C4 binding proteinA217 100 µL Anti-human C5A219 100 µL Anti-human C6A221 100 µL Anti-human C7A223 100 µL Anti-human C9A225 100 µL Anti-human Factor B (Ba)A227 100 µL Anti-human Factor B (Bb)A229 100 µL Anti-human Factor H#1A231 100 µL Anti-human Factor I#2A233 100 µL Anti-human Factor P#1A235 100 µL Anti-human Factor P#2A237 100 µL Anti-human S-Protein (vitronectin)A239 100 µL Anti-human SC5b-9 (TCC neoantigen)A241 100 µL Anti-human Clusterin
(SP40, 40 andApo J)A247 100 µL Anti-human Factor I#1A249 100 µL Anti-human C8A250 100 µL Anti-human C3d (neoantigen)A251 100 µL Anti-human C4d (neoantigen)A252 100 µL Anti-human Bb (neoantigen)A253 0.5 mL Anti-human C4 (C4d)A254 100 µL Anti-human Factor H#2A255 100 µL Anti-human Factor H#3For information on specific monoclonal antibodies and theirapplications, contact Quidel technical service.
CIC-C1q
IVD
Circulating Immune Complex-C1q
A001 (CE)
96 wells
Serum/EDTA Plasma10 µL
1.0 µg Eq/mL
0.1–3.2%
0.3–3.9%
Am, Cm,Rm, B
3
0
2.5 hrs
Normal2.1 µg/Eq/mL
C1-INH Plus
IVD
Functional C1-Inhibitor Protein
A037 (CE)
96 wells
Serum/EDTA Plasma10 µL
3.3–5.4%
5.7–10%
Rm, B
5
2
2 hrs
Normal≥68% mean normal
Equivocal41–67% mean normal
Abnormal≤40% mean normal
CH50 Eq
IVD
CH50
A018 (CE)
96 wells
Serum 14 µL
3.2–4.5%
5.4–8.7%
Cm
5
2
3.5hrs
Normal133±54 CH50 U
Eq/mL
Bb Plus
IVD
Bb Fragment
A027 (CE)
96 wells
Serum 25 µLEDTA Plasma 50 µL
0.018 µg/mL
0.033 µg/mL
0.836 µg/mL
2.4–4.0%
6.2–9.1%
P, Cm, Rm
5
2
1.5 hrs
Serum0.0–7.6 µg/mL
EDTA Plasma0.3–1.7 µg/mL
iC3b
RUO
iC3b Fragment
A006
96 wells
Serum/EDTA or Heparin Plasma
100 µL
None
3
2
1.5 hrs
None
CIC-Raji
IVD
Circulating Immune Complex-Raji Cell
Replacement
A002 (CE)
96 wells
Serum/Plasma10 µL
4.0 µg Eq/mL
3–9%
4–30%
None
5
2
2.5 hrs
Normal5.0 µg Eq/mL
SLE15.8 µg Eq/mL
RA13.7 µg Eq/mL
Marker
Cat. No.
Tests Per Kit
Specimen Volume
Limit of Detection
Lower Limit ofQuantitation
Upper Limit ofQuantitation
Intra-AssayVariation (CV)
Inter-AssayVariation (CV)
Animal Crossreactivity†
No. of Standards
No. of Controls
Total Assay Time
Sample Values
†Crossreactivity: (R) Rat, (M) Mouse, (Gp) Guinea Pig, (Rb) Rabbit, (Cm) Cynomolgous monkey, (Rm) Rhesus monkey, (B) Baboon, (P) Pig, (D) Dog, (S) Sh
Ba
RUO
Ba Fragment
A033 / A034 (CE)
96 wells
Serum 10 µLEDTA Plasma 25 µL
Urine 10 µL
0.011 ng/mL
0.033 ng/mL
3.239 ng/mL
2.2–3.3%
2.4–8.1%
Am, Cm, Rm, D
5
2
2.5 hrs
Serum436–3362 ng/mL
EDTA Plasma226–2153 ng/mL
Urine0.6–27 ng/mL
C4d
RUO
C4d Fragment
A008
96 wells
Serum/EDTA Plasma10 µL
0.001 µg/L
0.022 µg/L
6.1–9.7%
8.5–11.2%
B
5
2
1.5 hrs
Serum0.0–9.7 µg/mL
EDTA Plasma0.0–7.7 µg/mL
C3a Plus
RUO
C3a Fragment(Anaphylatoxin)
A031 / A032 (CE)
96 wells
Serum/EDTA Plasma10 µL
0.012 ng/mL
0.023 ng/mL
2.531 ng/mL
4.5–5.3%
5.9–19.6%
Am, Cm, Rm
5
2
2.5 hrs
Serum71–589.2 ng/mL
Plasma33.8–268.1 ng/mL
SC5b-9 Plus
RUO
SC5b-9
A020 / A029 (CE)
96 wells
Serum 10 µLEDTA or Citrated
Plasma 50 µL
3.7 ng/mL
8.8 ng/mL
1.6–6.8%
5.0–13.1%
Rm, B, Cm, Rb, Am, Pm
5
2
2 hrs
None
C5a
RUO
C5a Fragment(Anaphylatoxin)
A021 / A025 (CE)
96 wells
Serum 10 µLEDTA or Citrated
Plasma 20 µL
0.01 ng/mL
0.05 ng/mL
3.5–3.9%
7.1–13%
None
5
2
2.5 hrs
Serum13.4–179 ng/mL
Plasma0.37–74.33 ng/mL
C4a
RUO
C4a Fragment(Anaphylatoxin)
A035 / A036 (CE)
96 wells
Serum/EDTA Plasma10 µL
0.29 ng/mL
5.0 ng/mL
61 ng/mL
3.7–4.3%
4.0–4.4%
Am, Cm, Rm
5
2
2.5 hrs
Serum20.9–4437 ng/mL
Plasma384–8168 ng/mL
Pan-Specific C3
RUO
Depletion of C3
20261
96 wells
Serum/Plasma20 µL
Bv, Ck, D, Gp,P, H, Mp, Rb,
R, S, T, M
0
1
3 hrs
None
heep, (G) Goat, (C) Cow, (H) Horse, (Ct) Cat, (Ck) Chicken, (Bv) Bovine, (Mp) Mini pig, (T) Turkey, (Am) African green monkey, (Pm) Pigtail monkey
Biochemical markers of bone resorption and formation reflect the underlying process of bone turnover and may
be useful in supplementing the information from bone mineral density (BMD) testing. Many studies have
confirmed the importance of various biochemical bone markers both in clinical monitoring and assessment of
patients at risk for osteoporosis and related diseases as well as in research into the nature of these states.
Examples of specific serum and urine markers that reflect overall bone turnover include total pyridinolines, and
free and total deoxypyridinolines, as well as newer markers like helical peptide. Formation markers include bone
specific alkaline phosphatase, carboxyterminal propetide of Type 1 collagen (CICP, PICP) and osteocalcin.
The Specialty Products Group at Quidel manufactures a variety of enzyme immunoassays or biochemical
markers of bone turnover that may be useful as independent predictors of fracture risk and rate of bone loss.
Branded under the MicroVue name, additional information regarding the breadth of tools and reagents for
bone health research can be found on our website.
Research to Rapids
DIAGNOSTIC EIA KITSFor In Vitro Diagnostic Use*
Diagnostic kits for assessment of bone/joint activity.
Catalog # Qty Description 8007 (CE) 1 kit MicroVue DPD EIA
Deoxypyridinoline crosslinks (urine)8010 (CE) 1 kit MicroVue PYD EIA
Pyridinium crosslinks (urine)8012 (CE) 1 kit MicroVue BAP EIA Bone
Alkaline Phosphatase8043 (CE) 1 kit MicroVue Calcitonin EIA
Calcitonin (1-32)8044 (CE) 1 kit MicroVue Intact PTH EIA
Intact Parathyroid Hormone (1-84) 8046 (CE) 1 kit MicroVue 25-OH Vitamin D EIA
Total 25-OH Vitamin D
*All MicroVue Bone IVD products are also CE marked
REAGENTSCatalog # Quantity Description 4634 1 each Streptavidin Coated 96-well Plate
(for biotinylated molecules)**4703 55 mL Wash Buffer Concentrate**4704 55 mL Assay Buffer**4838 1 each Hydrolysis Unit — 96-well heating
block with lid for use with 8032**4935 40/bag 30k MWCO Spinfilters**
ImmutopicsDiluent30-2531 10 mL Rat PTH Sample Diluent**30-3131 10 mL Human PTH Sample Diluent**30-6631 10 mL Human FGF-23 Sample Diluent**
CONTROLSCatalog # Quantity Description 4818 set of 4 CICP Controls – serum**4819 set of 4 Osteocalcin Controls – serum**4820 set of 4 BAP Controls – serum**4821 set of 4 YKL-40 Controls**4822 set of 4 Dpd Controls – urine**4823 set of 4 Pyridinoline Controls – urine**4824 set of 4 Pyridinoline Controls – serum**4936 set of 4 Helical Peptide Controls – urine** 8004 750 µL Pyd/Dpd HPLC Calibrator** 8006 5 mL HPLC Internal Standard**
EIA KITS FOR MARKERS OF DIABETESAND OBESITY
These kits allow for the assessment of markers fordiabetes and obesity.
Catalog # Quantity Description TE1011 1 kit Human Intact Proinsulin ELISA**
Proinsulin (intact)TE1016 1 kit Human Leptin ELISA** LeptinTE1014 1 kit Total Human Adiponectin ELISA**
Adiponectin (total)
EIA KITS FOR MARKERS OF BONE ANDTISSUE REMODELING
These kits allow for the analysis of bone markers andtissue remodeling in serum, plasma and otherbiological fluids.
Catalog # Qty Description 8002 1 kit MicroVue Osteocalcin EIA**
Osteocalcin (intact)8003 1 kit MicroVue CICP EIA** C-Terminal
Propeptide of type I Collagen8009 1 kit MicroVue Creatinine EIA**8019 1 kit MicroVue Serum PYD EIA**
Pyridinoline crosslinks (serum)8020 1 kit MicroVue YKL-40 EIA** YKL-408022 1 kit MicroVue Helical Peptide EIA**
Helical Peptide a1(I) 620-6338032 1 kit MicroVue tDPD EIA**
Total Deoxypyridinoline8033/8036 (CE) 1 kit MicroVue TRAP5b EIA**
Tartrate-resistant acid phosphatase 5b (TRAcP5b)
8034 1 kit MicroVue OPG EIA**Osteoprotegerin
TE1023HS 1 kit Human Sclerostin HS EIA**Sclerostin High Sensitivity
TE1018-2 1 kit Human Hyaluronic Acid Plus ELISA**Hyaluronic Acid (HA)
ImmutopicsHuman60-6600 1 kit Human Intact FGF-23 EIA**60-6100 1 kit Human FGF-23 (C Term) EIA**60-3000 1 kit Human Bioactive PTH (1-84) EIA**60-3100 1 kit Human PTH EIA**60-3900 1 kit High Sensitivity Human PTH
(1-34) EIA**60-4000 1 kit Anti-Human PTH (1-34)
Antibody EIA**Mouse and Rat60-6800 1 kit Mouse/Rat Intact FGF-23**60-6300 1 kit Mouse FGF-23 (C Term) EIA**60-2305 1 kit Mouse PTH 1-84 EIA**60-2700 1 kit Rat Bioactive Intact PTH EIA**60-2500 1 kit Rat Intact PTH EIA**60-1305 1 kit Mouse Osteocalcin EIA**60-1505 1 kit Rat Osteocalcin EIA**Porcine and Bovine60-3305 1 kit Porcine Intact PTH EIA**60-3500 1 kit Bovine Intact PTH EIA**Canine60-3800 1 kit Canine Intact PTH EIA**
ANTIBODIES AND ANTIGENSCatalog # Quantity Description 4817 0.1 mg Mouse Anti-CICP antibody**4807 0.02 mg H-Dpd**4811 0.1 mg Mouse Anti-Dpd antibody**4805 0.02 mg H-Pyd**4809 0.1 mg Mouse Anti-Pyd antibody** 4813 0.1 mg Mouse Anti-YKL-40 antibody** 4815 0.1 mg Rabbit Anti-YKL-40 antibody**A442 25 µg YKL-40 Purified Protein
**Sold in the U.S. for Research Use Only. Not for use in diagnostic procedures.
BAP
IVD
Bone specific alkaline
phosphatase (BAP)
8012 (CE)
96 wells
Formation
Serum 20 µL
0.7 U/L
2 U/L
140 U/L
3.9–5.8%
5.0–7.6%
Rb, Cm, Rm, B, P, D, S, G, C, H
6
2
3.5 hrs
Females(Ages 25–44)11.6–29.6 U/L
Males(Ages ≥25)
15.0–41.3 U/L
OC
RUO
Intact Osteocalcin
8002
96 wells
Formation
Serum 25 µL
0.45 ng/mL
4.8–10.0%
4.8–9.8%
Gp, Rb, Cm, P, S, G, C, H
6
2
3.6 hrs
Adult3.7–10.0 ng/mL
Ty
S
6
11
PYD
IVD
Pyridinoline(PYD)
8010 (CE)
96 wells
Resorption
Urine 50 µL
7.5 nmol/L
15 nmol/L
750 nmol/L
6.6–9.9%
3.9–11.2%
R, M, Gp, Rb, Cm, Rm, P, D, S, H
6
2
4 hrs
Females(Ages >25)
(premenopausal)16.0–37.0 nmol
PYD/mmolCreatinine
Males12.8–25.6 nmol
PYD/mmolCreatinine
Calcitonin
IVD
Calcitonin
8043 (CE)
96 wells
Inhibit Resorption
Serum 100 µL
1.0 pg/mL
2.8–5.7%
6.1–7.4%
None
6
2
5 hrs
Females0.1–10.9 pg/mL
Males0.2–27.7 pg/mL
Intact PTH
IVD
ParathyroidHormone
8044 (CE)
96 wells
Homeostasis
Serum/EDTAPlasma 25 µL
1.57 pg/mL
3.7–6.1%
2.8–3.6%
None
6
2
4 hrs
Adult10.4–66.5 pg/mL
Vitamin D
IVD
25-OH Vitamin D
8046 (CE)
96 wells
Resorption
Serum 50 µL
2.81 ng/mL
4.32 ng/mL
2.5–7.8%
4.3–9.2%
None
6
2
3 hrs
Adult(21–92)
4.9–88.6 ng/mL
DPD
IVD
Deoxypyridinoline (DPD)
8007 (CE)
96 wells
Resorption
Urine 50 µL
1.1 nmol/L
3 nmol/L
300 nmol/L
4.3–8.4%
3.1–4.8%
R, M, Gp, Rb, Cm, Rm, Sm, B, P, D, S, C, H
6
2
3 hrs
Females(Ages 25–44)3.0–7.4 nmol
DPD/nmolCreatinine
Males(Ages 25–55)2.3–5.4 nmol
DPD/nmolCreatinine
Marker
Cat. No.
Tests Per Kit
Bone/JointActivity
Specimen Volume
Limit of Detection
Lower Limit ofQuantitation
Upper Limit ofQuantitation
Intra-AssayVariation (CV)
Inter-AssayVariation (CV)
Animal Crossreactivity†
No. of Standards
No. of Controls
Total Assay Time
Sample Values
†Crossreactivity: (R) Rat, (M) Mouse, (Gp) Guinea Pig, (Rb) Rabbit, (Cm) Cynomolgous monkey, (Rm) Rhesus monkey, (Sm) Squirrel monkey, (B) Baboon, (P) Pig, (
CICP
RUO
ype I Collagen C-Terminal
8003
96 wells
Collagen Synthesis
Serum 25 µL
0.2 ng/mL
1 ng/mL
80 ng/mL
5.5–6.8%
5–7%
Rb, Cm, Rm,
6
2
4 hrs
Adult69–103 ng/mL
Children10–966 ng/mL
Helical Peptide
RUO
Type I Collagen a1 helical peptide
620-633
8022
96 wells
Resorption
Urine 20 µL
8 µg/L
4.0–8.1%
7.3–16.9%
R, M, Gp, Rb, Cm, Rm, B, P, D, S, G,
C, H, Ct
6
2
19–25 hrs
Adult50.7 µg/mmol
tDPD
RUO
Total Deoxypyridinoline
(DPD)
8032
96 wells
Resorption
Serum 100 µLUrine 50 µL
0.5 nmol/L
1 nmol/L
100 nmol/L
5.3–12.1%
10.1–16.8%
R, M, Gp, Rb, Cm, Rm, B, P, D, S,
C, H, Ct, Sq
6
2
23–25 hrs
Females(Ages 25–44)
2.56–4.79 nmol/L
Males(Ages 25–55)
2.25–4.44 nmol/L
Serum PYD
RUO
Pyridinoline(PYD)
8019
96 wells
Resorption
Serum 25 µL
0.4 nmol/L
6.3–14.8%
8.7–11.6%
R, M, Gp, Rm, B, P, D, C, H, Ct
1
2
20–26 hrs
Adult(25–55)
1.09–2.79 nmol/L
TRAP5b
RUO
Tartrate-resistant acid phosphatase
isoform 5b
8033 / 8036 (CE)
96 wells
Resorption
Serum/Heparin Plasma 50 µL
0.24 U/L
1.9–2.2%
2.0–3.0%
None
5
2
2 hrs
Females(Ages 30–44)
(premenopausal)2.9±1.4 U/L
(Ages ≥50)(postmenopausal)
4.3±1.5U/L
Males(Ages ≥20)4.0±1.4 U/L
OPG
RUO
Osteoprotegerin(OPG)
8034
96 wells
Resorption
Serum/Citrate, EDTA or Heparin Plasma
100 µL
0.13 pmol/L
2.1–3.5%
4.2–6.2%
Rm, B
6
2
3 hrs
Adult5.7±0.42 pmol/L
Sclerostin
RUO
Sclerostin
TE1023HS
96 wells
Formation
Serum/EDTA or Heparin Plasma
25 µL
0.009 ng/mL
0.058 ng/mL
3.5 ng/mL
3.7–4.2%
4.3–4.8%
None
6
2
5 hrs
Females(premenopausal)
0.50 ng/mL
(postmenopausal)0.45 ng/mL
Males0.59 ng/mL
Hyaluronic Acid
RUO
Hyaluronic Acid
TE1018-2
96 wells
Homeostasis
Serum/EDTA Plasma 100 µL
2.7 ng/mL
2.8–2.9%
4.7–6.5%
None
6
2
3 hrs
Females(premenopausal)
20.1 ng/mL
(postmenopausal)50.3 ng/mL
Males42.6 ng/mL
D) Dog, (S) Sheep, (G) Goat, (C) Cow, (H) Horse, (Ct) Cat, (Ch) Chimpanzee, (Sq) Squirrel
Quidel | Specialty Products | Research to Rapids® | quidel.com | 800.874.1517 | 858.552.1100
1463MI0315D-2 (04/16)